Form 4: Treace Medical Officer Sells Shares for Tax Withholding
Insider Transaction Report
Treace Medical Concepts' Chief Innovation Officer, Sean Scanlan, disposed of 9,814 common shares to cover tax obligations related to equity vesting.
Summary
- Sean F. Scanlan, Chief Innovation Officer of Treace Medical Concepts, Inc. (TMCI), reported a change in beneficial ownership.
- On August 9, 2025, Scanlan disposed of 9,814 shares of common stock.
- This disposition was made to satisfy tax withholding obligations, indicated by a transaction price of $0 per share.
- Following this transaction, Scanlan beneficially owns 373,807 shares of common stock, which includes 284,798 restricted stock units.
Sentiment
Score: 5
Explanation: This is a routine insider transaction for tax withholding purposes, which is a neutral event and not indicative of positive or negative company performance or outlook.
Stakeholder Impact
- Shareholders: Provides transparency on insider stock ownership and routine transactions, but this specific event has minimal direct impact on share value or company operations.
Key Dates
| Date | Description |
|---|---|
| 08/09/2025 | Date of transaction for the disposition of common stock. |
| 08/12/2025 | Date the Form 4 was signed by the reporting person's attorney-in-fact. |
Keywords
Treace Medical Concepts, TMCI, Sean Scanlan, insider transaction, Form 4, stock disposition, tax withholding, Chief Innovation Officer
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.